Astellas expands alliance with Seattle Genetics for antibody-drug conjugates
This article was originally published in Scrip
The Astellas group company Agensys has paid $12 million to extend its collaboration with Seattle Genetics for the development of antibody-drug conjugates (ADCs). The deal could be worth up to $350 million in development and sales milestones to Seattle Genetics should all the new projects be successful.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.